Analyst Price Target is $32.00
▲ +2,439.68% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for NRx Pharmaceuticals in the last 3 months. The average price target is $32.00, with a high forecast of $45.00 and a low forecast of $19.00. The average price target represents a 2,439.68% upside from the last price of $1.26.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in NRx Pharmaceuticals.
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Read More
